BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
People who talk with their hands seem more clear and persuasive – new research - 2Creative Tech Contraptions That Will Work on Your Life
- 3Gulf countries roll out more autonomous taxis
- 4German mid-sized firms gloomy on outlook, survey finds
- 5The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- Incredible Travel Objections for Craftsmanship Darlings to Visit
- How will the universe end?
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- Dad issues urgent plea to find stem cell donor for his son
- Fireballs and a full moon. Here’s how to see two celestial events this week
- Online business Stages for Little Retailers
- The most effective method to Pick The Right Speakers
- An eye for an eye: People agree about the values of body parts across cultures and eras
- Whale stranded off Germany for days found stuck again
